Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Millennium (NASDAQ:MLNM) said that 2007 U.S. sales of Velcade bortezomib rose 20%
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury